FibroGen to Report Second Quarter 2022 Financial Results
25 juil. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
Boehringer Ingelheim and F. Hoffman La Roche Among Key Players in the Idiopathic Pulmonary Fibrosis Market | GlobalData Plc
14 juil. 2022 06h45 HE
|
GlobalData Plc
LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- The “Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecasts to 2029 (Event Driven Update)” report offered by GlobalData Plc provides an overview...
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
16 mai 2022 00h05 HE
|
Angion Biomedica Corp.
-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF...
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 16h01 HE
|
FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
Global Interstitial Lung Disease Market to Surpass US$ 2453.5 Million by 2028, Says Coherent Market Insights (CMI)
27 déc. 2021 08h30 HE
|
CMI
SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial lung disease market is estimated to be valued at US$ 1578.9 million in 2021 and is expected...
FibroGen to Present at Upcoming Investor Conferences
02 nov. 2021 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following...
Global Idiopathic Pulmonary Fibrosis Disease Treatment Markets, 2018-2019 & 2020-2024
08 sept. 2021 03h58 HE
|
Research and Markets
Dublin, Sept. 08, 2021 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets" report has been added to ResearchAndMarkets.com's offering.The current report...
Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space
17 août 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space The Idiopathic Pulmonary...
Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Report 2021 with 10-Year Disease Incidence and Prevalence Forecasts
13 juil. 2021 05h13 HE
|
Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
11 mai 2021 07h01 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...